Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection

Lee, Bongyong; Mazar, Joseph; Aftab, Mohammad; Qi, Feng; Shelley, John; Li, Jian Liang; Govindarajan, Subramaniam S.; Valerio, Felipe; Rivera, Inoel; Thurn, Tadzia; Tran, Tien Anh; Kameh, Darian; Patel, Vipul; Perera, Ranjan J.

doi:10.1016/j.jmoldx.2014.06.009

Cited by 76 publications

(56 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence suggests that lncRNAs may function as pro-apoptotic or anti-apoptotic regulators [22]. They are frequently dysregulated in various disease models [23]. In support of this notion, we show that UCA1 is downregulated in I/R-induced heart injury and that its expression is negatively correlated with the tumor suppressor p27.…”

Section: Discussionsupporting

confidence: 78%

Long Non Coding RNA-UCA1 Contributes to Cardiomyocyte Apoptosis by Suppression of p27 Expression

Liu

Daliang(²,

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Key WordsLong non coding RNA • UCA1 • Cardiomyocyte apoptosis • p27 Abstract Background/Aims: Urothelial carcinoma-associated 1 (UCA1) is a recently identified long non coding RNA (lncRNA). However, few studies have explored its role in cardiomyocytes after focal cardiac ischemia reperfusion injury (CIR). Methods: Rat CIR models were established using ligation of the Lower Anterior Descending artery (LAD). Cell apoptosis and reactive oxygen species (ROS) production in cardiac tissues were explored using immunohistochemistry and DHE staining. lncRNA expression patterns were detected using microarray and validated by qPCR. Cell viability and apoptosis were examined using MTT assay and flow cytometry. Results: CIR significantly induced cell apoptosis and ROS production in the rat model. The results of microarray demonstrated the reduced expression of UCA1, which was validated by qPCR. Follow-up experiments showed that UCA1 was involved in H 2 O 2 -induced cell apoptosis. We further showed that UCA1 negatively correlated with the expression of p27. Moreover, overexpression of p27 could induce primary cardiomyocyte apoptosis. Conclusions: Reduction of UCA1 levels plays a pro-apoptotic role in primary cardiomyocytes partially through stimulation of p27 protein expression. These results are in agreement with the observed levels of UCA1, p27 and apoptosis after cardiac I/R injury, suggesting that UCA1 might have an important role during I/R injury.

show abstract

Section: Discussionsupporting

confidence: 78%

Long Non Coding RNA-UCA1 Contributes to Cardiomyocyte Apoptosis by Suppression of p27 Expression

Liu

Daliang(²,

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Similarly, MALAT1 is significantly higher in the urine of men with a positive biopsy for PCa than in those with a negative biopsy . Some other lncRNAs with predictive values for PCa diagnosis alone and in combination include FR0348383, and AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559 and XLOC_009911 …”

Section: Lncrnas In Cancer Diagnosismentioning

confidence: 99%

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Gupta

Tripathi

2016

Intl Journal of Cancer

421

260

View full text Add to dashboard Cite

Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential. Some lncRNAs such as PCA3 is now routinely used in the clinic for the diagnosis of prostate cancer. Single nucleotide polymorphisms (SNPs) in lncRNAs can also be used as a predictor of cancer risk. Although ongoing studies continue to unravel the underlying mechanism, some lncRNAs have been used as therapeutic targets for the selective killing of cancer cells in patients. Thus lncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target. Companies such as the Curna Inc., MiNA Therapeutics Ltd. and RaNA Therapeutics Inc. have been taking steps to develop lncRNA based strategies against cancer. In this review, we discuss the potential of lncRNAs as biomarkers and therapeutic targets in cancer patients.

show abstract

“…SPRY4 intronic transcript 1 ( SPRY4‐IT1 ) is one of the lncRNAs highly upregulated in PC3 cells and in patient samples compared to non‐malignant prostate epithelial cells and matched normal prostate tissues . siRNA knockdown of SPRY4‐IT1 inhibited PC3 cellular proliferation and invasion, and increased apoptosis . SPRY4‐IT1 was easily detected in all prostate cancer samples with different Gleason scores (6–10) in an RNA chromogenic ISH assay .…”

Section: Lncrnas and Prostate Cancermentioning

confidence: 99%

Long non‐coding RNAs and prostate cancer

2017

View full text Add to dashboard Cite

Long non‐coding RNAs (lncRNAs) are RNA transcripts larger than 200 nucleotides that do not code for proteins the aberrant expression of which has been documented in various types of cancer, including prostate cancer. Lack of appropriate sensitive and specific biomarkers for prostate cancer has led to overdiagnosis and overtreatment, making lncRNAs promising novel biomarkers as well as therapeutic targets for the disease. The present review attempts to summarize the current knowledge of lncRNA expression patterns and mechanisms in prostate cancer, which contribute to carcinogenesis. In particular, we focused on lncRNAs regulated by androgen receptor and expressed in castration‐resistant prostate cancer.

show abstract

Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection

Cited by 76 publications

References 60 publications

Long Non Coding RNA-UCA1 Contributes to Cardiomyocyte Apoptosis by Suppression of p27 Expression

Long Non Coding RNA-UCA1 Contributes to Cardiomyocyte Apoptosis by Suppression of p27 Expression

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Long non‐coding RNAs and prostate cancer

Contact Info

Product

Resources

About